Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS

Francesc Artigas; Esther Schenker; Pau Celada; Michael Spedding; Laia Lladó-Pelfort; Noemi Jurado; Mercedes Núñez; Noemi Santana; Eva Troyano-Rodriguez; Maurizio S Riga; Hanna van den Munkhof; Anna Castañé; Hamdy Shaban; Thérèse M Jay; Anushree Tripathi; Bill P Godsil; Claude Sebban; Jean Mariani; Philippe Faure; Samir Takkilah; Zoe A Hughes; Chester J Siok; Mihaily Hajos; Karsten Wicke; Natalia Gass; Wolfgang Weber-Fahr; Alexander Sartorius; Robert Becker; Michael Didriksen; Jesper F Bastlund; Mark Tricklebank; Céline Risterucci; Andreas Meyer-Lindenberg; Adam J Schwarz

doi:10.1038/nrd.2016.205

Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS

Nat Rev Drug Discov. 2017 Jan;16(1):1-2. doi: 10.1038/nrd.2016.205. Epub 2016 Nov 4.

Authors

Francesc Artigas^{1

2

3}, Esther Schenker⁴, Pau Celada^{1

2

3}, Michael Spedding⁴, Laia Lladó-Pelfort^{1

2

3}, Noemi Jurado^{1

2

3}, Mercedes Núñez^{1

2

3}, Noemi Santana^{1

2

3}, Eva Troyano-Rodriguez^{1

2

3}, Maurizio S Riga^{1

2

3}, Hanna van den Munkhof^{1

2

3}, Anna Castañé^{1

2

3}, Hamdy Shaban⁵, Thérèse M Jay⁶, Anushree Tripathi⁶, Bill P Godsil⁶, Claude Sebban⁷, Jean Mariani⁷, Philippe Faure⁷, Samir Takkilah⁷, Zoe A Hughes⁸, Chester J Siok⁸, Mihaily Hajos⁸, Karsten Wicke⁹, Natalia Gass¹⁰, Wolfgang Weber-Fahr¹⁰, Alexander Sartorius¹⁰, Robert Becker¹⁰, Michael Didriksen¹¹, Jesper F Bastlund¹¹, Mark Tricklebank¹², Céline Risterucci¹³, Andreas Meyer-Lindenberg¹⁰, Adam J Schwarz¹⁴

Affiliations

¹ Department of Neurochemistry and Neuropharmacology, Institut d'Investigacions Biomèdiques de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), 08036 Barcelona, Spain.
² CIBERSAM (Centro de Investigació Biomédica en Red de Salud Mental), 28029 Madrid, Spain.
³ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
⁴ Institute de Recherches SERVIER, 78290 Croissy sur Seine, France.
⁵ Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
⁶ UMR_S 894 Inserm, Centre de Psychiatrie et Neurosciences, 75014 Paris, France.
⁷ Université Pierre et Marie Curie (UPMC), CNRS UMR, 8246, INSERM U1130, 75252 Paris, France.
⁸ Pfizer Global Research, 610 Main Street, Cambridge, Massachusetts 02139, USA.
⁹ AbbVie Deutschland GmbH &Co. KG, Knollstrasse, Ludwigshafen 67061, Germany.
¹⁰ Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim 68159, Germany.
¹¹ Lundbeck A/S, 2500 Valby, Denmark.
¹² Lilly Centre for Cognitive Neuroscience, Eli Lilly &Co. Ltd, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK.
¹³ CNS Biomarker, Pharmaceuticals Division, F. Hoffmann-La Roche, 4070 Basel, Switzerland.
¹⁴ Lilly Research Laboratories, 835 S Delaware Street, Indianapolis, Indiana 46285, USA.

PMID: 27811930
DOI: 10.1038/nrd.2016.205

Abstract

Despite the vast amount of research on schizophrenia and depression in the past two decades, there have been few innovative drugs to treat these disorders. Precompetitive research collaborations between companies and academic groups can help tackle this innovation deficit, as illustrated by the achievements of the IMI-NEWMEDS consortium.

MeSH terms

Antidepressive Agents / pharmacology*
Antidepressive Agents / therapeutic use
Antipsychotic Agents / pharmacology*
Antipsychotic Agents / therapeutic use
Depressive Disorder / drug therapy
Depressive Disorder / physiopathology
Drug Industry
Humans
Mental Disorders / physiopathology*
Neural Pathways / physiopathology*
Schizophrenia / drug therapy
Schizophrenia / physiopathology

Substances

Antidepressive Agents
Antipsychotic Agents